<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04683614</url>
  </required_header>
  <id_info>
    <org_study_id>201920025.2P</org_study_id>
    <nct_id>NCT04683614</nct_id>
  </id_info>
  <brief_title>Intraoperative Norepinephrine Versus Fresh Frozen Plasma in Patients Undergoing HIPEC to Reduce Renal Insult</brief_title>
  <official_title>Intraoperative Norepinephrine Versus Fresh Frozen Plasma in Patients Undergoing HIPEC to</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      comparing the effect of low dose norepinephrine infusion versus fresh frozen plasma in&#xD;
      patients undergoing HIPEC to reduce renal insult&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To compare the efficacy of maintaining intraoperative hemodynamic stability through infusing&#xD;
      low dose norepinephrine versus fresh frozen plasma in patients undergoing cytoreductive&#xD;
      surgery and heated intraperitoneal chemotherapy in cancer patients undergoing cytoreductive&#xD;
      surgery and heated intraperitoneal chemotherapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2020</start_date>
  <completion_date type="Anticipated">December 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Renal insult</measure>
    <time_frame>24 hours</time_frame>
    <description>Creatinine level increase 0.3 mg/dl above preoperative baseline</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>Fresh frozen plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>early administration of fresh frozen plasma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose norepinephrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose epinephrine 5 mic/kg/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norepinephrine</intervention_name>
    <description>5 mic/kg/hr norepinephrine</description>
    <arm_group_label>Low dose norepinephrine</arm_group_label>
    <other_name>low dose norepinephrine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fresh frozen plasma</intervention_name>
    <description>early administration of fresh frozen plasma</description>
    <arm_group_label>Fresh frozen plasma</arm_group_label>
    <other_name>Blood products</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA I and II&#xD;
&#xD;
          -  World Health Performance Status â‰¤2&#xD;
&#xD;
          -  scheduled for CRS/HIPEC operations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient's refusal&#xD;
&#xD;
          -  allergy to any of the used drugs&#xD;
&#xD;
          -  impaired renal or liver functions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walaa Y Elsabeeny, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Walaa Y Elsabeeny, MD</last_name>
    <phone>01007798466</phone>
    <phone_ext>002</phone_ext>
    <email>walaa.elsabeeny@nci.cu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed A Elramely, MD</last_name>
    <phone>01005125124</phone>
    <phone_ext>002</phone_ext>
    <email>mramely@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Walaa Y Elsabeeny</name>
      <address>
        <city>Cairo</city>
        <zip>11796</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walaa Y Elsabeeny, MD</last_name>
      <phone>01007798466</phone>
      <phone_ext>002</phone_ext>
      <email>Walaa.elsabeeny@nci.cu.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed A Elramely, MD</last_name>
      <phone>01005125124</phone>
      <phone_ext>002</phone_ext>
      <email>mramely@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Walaa Youssef Elsabeeny</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

